Technology Wins at CES Asia 2017
The third annual CES Asia shattered expectations and broke records while cementing the event as the region’s premier showcase for the consumer technology industry in the Eastern Hemisphere. With cutting edge technology around every corner, CES Asia 2017 buzzed with global exhibitors, influential media and industry leaders coming together in China to celebrate innovation, build partnerships and learn about the latest in tech - all in one place. CES Asia is owned and produced by the Consumer Technology Association (CTA)™ and co-produced by Shanghai Intex Exhibition Co., Ltd. (Shanghai Intex).
CES Asia 2017 broke records from previous years. This year’s show floor covered 40,000 gross square meters with more than 460 exhibiting companies from 22 countries, regions and territories. More than 1,200 members of the media navigated the five exhibit halls at CES Asia, where tech products across 19 categories were showcased over three days. CES Asia 2017 featured new product categories in augmented/virtual reality, drones and the Internet of Things (IoT), representing the full ecosystem of the technology industry. Designed to showcase major brands and innovative startups, CES Asia 2017 was a curated event, turning down hundreds of companies to ensure a quality event experience for both exhibitors and attendees.
“CES Asia was an overwhelming success. The show footprint has doubled in the last three years, reinforcing our event as China’s must-attend event for the technology community,” said Gary Shapiro, president and CEO, CTA. “With access to industry experts, the latest in consumer market trends, global media and much more, the value of this event is unparalleled for attendees, exhibitors, media and conference speakers alike. I can’t wait to see what CES Asia 2018 will bring!”
“Every year I’ve seen more content, more companies, more attendees and I think the platform continues to grow. It’s very exciting to be a part of it,” said Brian McClure, director of global innovation sourcing (Shanghai), at Johnson and Johnson Innovation.
China’s booming economy and expansive marketplace attracts global tech talent, entrepreneurs and innovators to its largest city. Shanghai, the home of CES Asia, is a leading innovation hub, both regionally and globally. CES Asia 2017 was filled with energy, excitement and innovation. Those in attendance learned about the newest technology trends from major tech players. Interactive exhibits provided hands-on experiences with the latest innovations in self-driving vehicles, drones, wearables and more. Companies gained insight into consumer market trends from CTA senior executives and market-leading industry experts at a packed conference program emphasizing the important role of disruptive technology in bettering the world. With record breaking numbers of industry professionals, top media and potential investors in attendance, startups and global brands utilized CES Asia to launch products and expand their brands.
“CES Asia is the region’s premier technology event and we were delighted to have the opportunity to showcase JD.com’s latest developments,” said Chen Zhang, CTO of JD.com and a keynote speaker at the event. “With AI enhanced e-commerce and other technologies creating greater efficiencies and better user experiences to revolutionize retail, JD.com utilized CES Asia to demonstrate our latest technology innovations and share our insights.”
By bringing industry heavyweights, influential media and technology experts to Shanghai, CES Asia strengthens the city’s global tech standing and influence. The event lends credibility to Shanghai’s rapidly growing technology community, creating a robust atmosphere for meaningful and strategic partnerships to form across the industry.
“This event is very very successful and has a wide effect for popularity among all the people here in China, in Asia, so we will continue to be here year after year,” said Aaron Chow, head of marketing (Hong Kong & China), Monster Inc.
CES Asia will return to Shanghai June 13-15, 2018. Visit CESAsia.com for the latest CES Asia 2017 news, photos and more.
For questions about exhibiting at CES Asia, contact Brian Moon at bmoon@CTA.tech or +1 703-907-4351. Visit CESAsia.com for access to b-roll.
About CES Asia:
Owned and produced by the Consumer Technology Association (CTA)TM and co-produced by Shanghai Intex Exhibition Co., Ltd (Shanghai Intex), CES Asia is the premier event for the consumer technology industry, showcasing the full breadth and depth of the innovation value-chain in the Asian marketplace. Key global businesses come to this new event to grow and reinforce their brand by showcasing the latest products and technologies to consumer tech industry executives, foreign buyers, international media and a limited number of consumers from China. Attendees have exclusive access to some of the largest brands from China and around the world, while celebrating the innovation that defines the consumer technology sector.
About Consumer Technology Association:
Consumer Technology Association (CTA) is the trade association representing the $321 billion U.S. consumer technology industry, which supports more than 15 million U.S. jobs. More than 2,200 companies – 80 percent are small businesses and startups; others are among the world’s best known brands – enjoy the benefits of CTA membership including policy advocacy, market research, technical education, industry promotion, standards development and the fostering of business and strategic relationships. CTA also owns and produces CES® – the world’s gathering place for all who thrive on the business of consumer technologies. Profits from CES are reinvested into CTA’s industry services.
About Shanghai Intex:
Shanghai Intex Exhibition Co., Ltd was originally the exhibition organizing business of Shanghai Intex, a pioneering exhibition organizer established in 1995. Shanghai Intex is jointly overseen by the China Council for the Promotion of International Trade (CCPIT) Shanghai and PNO Exhibition Investment (Dubai) Limited. Starting in 1998, Shanghai Intex has organized over 100 trade shows and conferences with a sum total exhibition space in excess of 2 million sqm. Shanghai Intex is comprised of professional teams with a wealth of experience in organizing major international events, covering the creative industry, healthcare, lifestyle, advanced manufacturing and consumer electronics.
UPCOMING EVENTS
-
Innovate! and Celebrate -
Register
October 9-11, San Francisco, CA -
CES Unveiled Paris -
Register
October 24, Paris, France -
CES Unveiled Amsterdam -
Register
October 26, Amsterdam, Netherlands -
CES 2018
January 9-12, Las Vegas, NV -
CES Asia 2018
June 13-15, Shanghai, China
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170726006363/en/
Contact information
Consumer Technology Association (CTA)
Teresa Hsu,
703-907-5259
thsu@CTA.tech
www.CESAsia.com
or
Bernice
Morquette, 703-907-7651
bmorquette@CTA.tech
www.CTA.tech
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK ® , a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 09:03:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least one non-class I mutation, meaning more patients would be eligible for a medicine that gets them closer to normal levels of sweat chloride,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. “CFTR modulators have already revolutionized the way we treat CF and I am encoura
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 08:02:00 EEST | Press release
Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of pridopidine in Europe and other select markets. Pridopidine is a potent and highly selective, orally administered sigma-1 receptor (S1R) agonist designed to regulate key neuroprotective mechanisms often impaired in neurodegenerative diseases such as HD and ALS. Under the terms of the agreement, Prilenia will receive an upfront payment of approximately €80 million plus up to €45 million in near-term development, regulatory, and commercial milestones. The total deal is valued at up to approximately €500 million in upfront and total milestone payments. In addition, Prilenia will receive tiered double-digit royalties on
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 08:00:00 EEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 12:36:00 EEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 20:00:00 EEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom